Literature DB >> 10438905

Cutting edge: dueling TCRs: peptide antagonism of CD4+ T cells with dual antigen specificities.

J M Robertson1, B D Evavold.   

Abstract

T cells expressing two different TCRs were generated by interbreeding 3A9 and AND CD4+ TCR transgenic mice specific for the hen egg lysozyme (HEL) peptide 48-62:I-Ak and moth cytochrome c (MCC) peptide 88-103:I-Ek peptide:MHC ligands, respectively. Peripheral T cells in the offspring express two TCR V beta-chains and respond to HEL and MCC. We observed minimal or no additive effects upon simultaneous suboptimal stimulation with both agonist peptides; however, an antagonist peptide for the 3A9 TCR was able to inhibit the response of the dual receptor T cells to MCC, the AND TCR agonist. This HEL antagonist peptide did not affect AND single transgenic T cells, indicating that the antagonism observed in the dual TCR cells is dependent on the presence of the HEL-specific 3A9 TCR. In contrast, anti-TCR Abs mediate receptor-specific antagonism. These results demonstrate that peptide antagonism exerts a dominant effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438905

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Cooperative enhancement of specificity in a lattice of T cell receptors.

Authors:  C Chan; A J George; J Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

Review 2.  Defining the parameters necessary for T-cell recognition of ligands that vary in potency.

Authors:  Neely E Kilgore; Mandy L Ford; Carrie D Margot; Daniel S Jones; Peter Reichardt; Brian D Evavold
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

4.  Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor.

Authors:  Ryan M Teague; Philip D Greenberg; Carla Fowler; Maria Z Huang; Xiaoxia Tan; Junko Morimoto; Michelle L Dossett; Eric S Huseby; Claes Ohlén
Journal:  Immunity       Date:  2008-05       Impact factor: 31.745

5.  Phenotypic model for early T-cell activation displaying sensitivity, specificity, and antagonism.

Authors:  Paul François; Guillaume Voisinne; Eric D Siggia; Grégoire Altan-Bonnet; Massimo Vergassola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

6.  Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope.

Authors:  Philip J Norris; Jennifer D Stone; Nadezhda Anikeeva; John W Heitman; Ingrid C Wilson; Dale F Hirschkorn; Margaret J Clark; Howell F Moffett; Thomas O Cameron; Yuri Sykulev; Lawrence J Stern; Bruce D Walker
Journal:  Mol Immunol       Date:  2005-10-07       Impact factor: 4.407

Review 7.  T cell recognition of weak ligands: roles of signaling, receptor number, and affinity.

Authors:  Lindsay J Edwards; Brian D Evavold
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

8.  Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8.

Authors:  Jennifer D Stone; David H Aggen; Adam S Chervin; Samanthi Narayanan; Thomas M Schmitt; Philip D Greenberg; David M Kranz
Journal:  J Immunol       Date:  2011-03-30       Impact factor: 5.422

Review 9.  Computational analysis of T cell receptor signaling and ligand discrimination--past, present, and future.

Authors:  Ronald N Germain
Journal:  FEBS Lett       Date:  2010-10-20       Impact factor: 4.124

Review 10.  Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy.

Authors:  Scheherazade Sadegh-Nasseri; Sarat K Dalai; Laura C Korb Ferris; Saied Mirshahidi
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.